Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial.

MLA

Tate, Molly K., et al. “Metformin in Conjunction With Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Long-Term Results of a Prospective Phase II Clinical Trial.” Anticancer Research, vol. 44, no. 1, Jan. 2024, pp. 133–37. EBSCOhost, https://doi.org/10.21873/anticanres.16795.

APA

Tate, M. K., Hernandez, M., Chang, J. Y., Lin, S. H., Liao, Z., Koshy, S. M., Skinner, H. D., & Chun, S. G. (2024). Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. Anticancer Research, 44(1), 133–137. https://doi.org/10.21873/anticanres.16795

Chicago

Tate, Molly K, Mike Hernandez, Joe Y Chang, Steven H Lin, Zhongxing Liao, Suja M Koshy, Heath D Skinner, and Stephen G Chun. 2024. “Metformin in Conjunction With Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Long-Term Results of a Prospective Phase II Clinical Trial.” Anticancer Research 44 (1): 133–37. doi:10.21873/anticanres.16795.